SILVERARC CAPITAL MANAGEMENT, LLC - Q3 2022 holdings

$296 Million is the total value of SILVERARC CAPITAL MANAGEMENT, LLC's 79 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .

 Value Shares↓ Weighting
 RENOVACOR INC*w exp 99/99/999$8,000
+33.3%
104,8280.0%0.00%
+50.0%
MSACW  MEDICUS SCIENCES ACQUISITION*w exp 02/12/202$1,000
-88.9%
49,9900.0%0.00%
-100.0%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-10-28
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
INTRA-CELLULAR THERAPIES INC12Q3 20237.8%
IMMUNOGEN INC12Q3 20238.3%
Morphic Holding Inc12Q3 20234.5%
UNUM THERAPEUTICS INC12Q3 20233.2%
INSMED INC12Q3 20233.5%
UNITED THERAPEUTICS CORP DEL12Q3 20232.2%
MERUS N V11Q3 20235.1%
VERACYTE INC11Q3 20234.9%
EVOGENE LTD11Q3 20231.6%
COMPUGEN LTD11Q3 20231.1%

View SILVERARC CAPITAL MANAGEMENT, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
SILVERARC CAPITAL MANAGEMENT, LLC Q3 2022 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Benitec Biopharma Inc.Sold outFebruary 08, 202300.0%
DELCATH SYSTEMS, INC.Sold outFebruary 08, 202200.0%

View SILVERARC CAPITAL MANAGEMENT, LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-02-14
SC 13G2024-02-14
SC 13G2024-02-14
SC 13G2024-02-14
13F-HR2023-11-13
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR2023-02-14
SC 13G/A2023-02-08
13F-HR2022-10-28

View SILVERARC CAPITAL MANAGEMENT, LLC's complete filings history.

Compare quarters

Export SILVERARC CAPITAL MANAGEMENT, LLC's holdings